Symptom Burden and Quality of Life Issues among Patients of Chronic Myeloid Leukemia on Long-term Imatinib Therapy

about

Symptom Burden and Quality of Life Issues among Patients of Chronic Myeloid Leukemia on Long-term Imatinib Therapy

Item

http://www.wikidata.org/entity/Q41601810

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Symptom Burden and Quality of ...... on Long-term Imatinib Therapy

@en

type

Item

label

Symptom Burden and Quality of ...... on Long-term Imatinib Therapy

@en

prefLabel

Symptom Burden and Quality of ...... on Long-term Imatinib Therapy

@en

P1476

Symptom Burden and Quality of ...... on Long-term Imatinib Therapy

@en

P2093

Prasanth Ganesan

http://www.w3.org/2001/XMLSchema#string

Radhika Unnikrishnan

http://www.w3.org/2001/XMLSchema#string

Surendran Veeraiah

http://www.w3.org/2001/XMLSchema#string

P2860

The role of observational studies in optimizing the clinical management of chronic myeloid leukemia

Measuring the symptom burden associated with the treatment of chronic myeloid leukemia

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.

Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective.

Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges.

Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications.

The impact of symptom burden on patient quality of life in chronic myeloid leukemia.

Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia.

P304

165-168

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/IJMPO.IJMPO_160_16

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28900325

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia

P932

5582554

http://www.w3.org/2001/XMLSchema#string